Recent Quotes (30 days)

You have no recent quotes
chg | %

Selecta Biosciences Inc  

(Public, NASDAQ:SELB)   Watch this stock  
Find more results for SELB
+0.72 (7.94%)
Mar. 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.35 - 10.42
52 week 7.95 - 24.02
Open 9.36
Vol / Avg. 783,700.00/317,845.00
Mkt cap 220.13M
P/E     -
Div/yield     -
EPS -3.21
Shares 22.35M
Beta     -
Inst. own 60%
Jun. 15, 2018
Selecta Biosciences Inc Annual Shareholders Meeting (Estimated) - 9:00a.m. EDT - Add to calendar
Mar. 27, 2018
Selecta Biosciences Inc at Needham Healthcare Conference - 9:30a.m. EDT - Add to calendar
Mar. 15, 2018
Q4 2017 Selecta Biosciences Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec. '17) 2017
Net profit margin -114964.70% -31556.04%
Operating margin -113394.10% -31138.65%
EBITD margin - -30451.21%
Return on average assets -74.37% -68.61%
Return on average equity -134.13% -122.36%
Employees 66 -
CDP Score - -


480 Arsenal Way
WATERTOWN, MA 02472-2891
United States - Map
+1-617-9231400 (Phone)
+1-617-9243454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

Officers and directors

Omid Farokhzad M.D. Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Werner Cautreels Ph.D. President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
John H. Leaman M.D. Chief Financial Officer, Principal Accounting Officer, Head of Corporate Strategy and Treasurer
Age: 45
Bio & Compensation  - Reuters
Lloyd Johnston Ph.D. Chief Operating Officer, Senior Vice President - Research & development
Age: 49
Bio & Compensation  - Reuters
Takashi Kei Kishimoto Ph.D. Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
David Abraham J.D. Chief Compliance Officer, General Counsel, Corporate Secretary
Age: 51
Bio & Compensation  - Reuters
Dmitry Ovchinnikov Managing Director, SelectaRUS, LLC
Bio & Compensation  - Reuters
Earl Sands M.D. Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Carl L. Gordon Ph.D. Director
Age: 52
Bio & Compensation  - Reuters
Edwin M. Kania Jr. Director
Bio & Compensation  - Reuters